Open AccessEtiology and Management of Anemia in Patients With Heart Failure: How Much Iron Is Missing?
Author(s) -
Silva Luis Beck da,
Rohde Luis E.,
Clausell Nadine
Publication year - 2008
Publication title -
congestive heart failure
Language(s) - English
Resource type - Journals
eISSN - 1751-7133
pISSN - 1527-5299
DOI - 10.1111/j.1751-7133.2008.07394.x
Subject(s) - medicine , anemia , heart failure , erythropoiesis , hepcidin , concomitant , etiology , intensive care medicine , iron deficiency , disease , clinical trial , ineffective erythropoiesis
Anemia is common among patients with heart failure (HF) and has been associated with worse prognosis. To date, it is not well known whether correction of anemia in these patients can improve outcome. Proposed modalities for correction of anemia have been either administration of erythropoiesis‐stimulating proteins, which appears plausible in patients with concomitant renal failure (so‐called cardiorenal syndrome), or iron supplementation, which is particularly attractive in patients with no overt renal failure and chronic disease anemia with some degree of iron deficiency. This article reviews the rationale for anemia correction and the latest randomized clinical trial assessing clinical utility of erythropoiesis‐stimulating proteins and/or iron supplementation through oral or intravenous administration in anemic HF patients.